[1] J. Hardy, A Hundred Years of Alzheimer’s Disease Research, Neuron. 52 (2006) 3–13. https://doi.org/10.1016/j.neuron.2006.09.016.
[2] P. Lei, S. Ayton, A.I. Bush, The essential elements of Alzheimer’s disease, J. Biol. Chem. 296 (2021) 100105. https://doi.org/10.1074/jbc.REV120.008207.
[3] T. Guo, D. Zhang, Y. Zeng, T.Y. Huang, H. Xu, Y. Zhao, Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease, Mol. Neurodegener. 15 (2020) 1–37. https://doi.org/10.1186/s13024-020-00391-7.
[4] M.M. Mesulam, A. Guillozet, P. Shaw, A. Levey, E.G. Duysen, O. Lockridge, Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine, Neuroscience. 110 (2002) 627–639. https://doi.org/10.1016/S0306-4522(01)00613-3.
[5] T.C. Dos Santos, T.M. Gomes, B.A.S. Pinto, A.L. Camara, A.M. De Andrade Paes, Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer’s disease therapy, Front. Pharmacol. 9 (2018) 1–14. https://doi.org/10.3389/fphar.2018.01192.
[6] M.K. Gupta, R. Vadde, In silico identification of natural product inhibitors for γ-secretase activating protein, a therapeutic target for Alzheimer’s disease, J. Cell. Biochem. 120 (2019) 10323–10336. https://doi.org/10.1002/jcb.28316.
[7] S. Dallakyan, A.J. Olson, Small-molecule library screening by docking with PyRx, Methods Mol. Biol. 1263 (2015) 243–250. https://doi.org/10.1007/978-1-4939-2269-7_19.
[8] D Studio, , Discovery Studio Life Science Modeling and Simulations, Researchgate.Net. (2008) 1–8.
[9] S.R. Kareti, S.M. Pharm, In Silico Molecular Docking Analysis of Potential Anti-Alzheimer’s Compounds Present in Chloroform Extract of Carissa carandas Leaf Using Gas Chromatography MS/MS, Curr. Ther. Res. - Clin. Exp. 93 (2020) 100615. https://doi.org/10.1016/j.curtheres.2020.100615.
[10] C.A. Lipinski, Lead- and drug-like compounds: The rule-of-five revolution, Drug Discov. Today Technol. 1 (2004) 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007.
[11] V. Replacement, V. Ch, C. Nh, Synthesis and Biological Activity, 19 (1991) 2402–2410.
[12] A.A.M. Alkhaldi, M.M. Al-Sanea, A. Nocentini, W.M. Eldehna, Z.M. Elsayed, A. Bonardi, M.F. Abo-Ashour, A.K. El-Damasy, M.S. Abdel-Maksoud, T. Al-Warhi, P. Gratteri, H.A. Abdel-Aziz, C.T. Supuran, R. El-Haggar, 3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies, Eur. J. Med. Chem. 207 (2020) 112745. https://doi.org/10.1016/j.ejmech.2020.112745.
[13] L. Subedi, B.P. Gaire, Tanshinone IIA: A phytochemical as a promising drug candidate for neurodegenerative diseases, Pharmacol. Res. 169 (2021) 105661. https://doi.org/10.1016/j.phrs.2021.105661.
[14] Z. Guan, J. Chen, X. Li, N. Dong, Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation, Biosci. Rep. 40 (2020) 1–11. https://doi.org/10.1042/BSR20201807.
[15] D. Luo, Sodium Tanshinone IIA Sulfonate Promotes Spinal Cord Injury Repair by Inhibiting BSCB Disruption In Vitro and In Vivo, (n.d.) 1–26.
[16] M. Ceylan, U.M. Kocyigit, N.C. Usta, B. Gürbüzlü, Y. Temel, S.H. Alwasel, İ. Gülçin, Synthesis, carbonic anhydrase I and II isoenzymes inhibition properties, and antibacterial activities of novel tetralone-based 1,4-benzothiazepine derivatives, J. Biochem. Mol. Toxicol. 31 (2017) 1–11. https://doi.org/10.1002/jbt.21872.